These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16652121)
1. Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Tomas D; Ulamec M; Hudolin T; Bulimbasić S; Belicza M; Kruslin B Prostate Cancer Prostatic Dis; 2006; 9(4):414-9. PubMed ID: 16652121 [TBL] [Abstract][Full Text] [Related]
2. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Tomas D; Kruslin B Prostate; 2004 Dec; 61(4):324-31. PubMed ID: 15389817 [TBL] [Abstract][Full Text] [Related]
3. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536 [TBL] [Abstract][Full Text] [Related]
4. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate. Zhang Y; Nojima S; Nakayama H; Jin Y; Enza H Oncol Rep; 2003; 10(1):207-11. PubMed ID: 12469170 [TBL] [Abstract][Full Text] [Related]
6. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. Katenkamp K; Berndt A; Hindermann W; Wunderlich H; Haas KM; Borsi L; Zardi L; Kosmehl H J Pathol; 2004 Jul; 203(3):771-9. PubMed ID: 15221936 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma. Koperek O; Scheuba C; Puri C; Birner P; Haslinger C; Rettig W; Niederle B; Kaserer K; Garin Chesa P Int J Oncol; 2007 Jul; 31(1):59-67. PubMed ID: 17549405 [TBL] [Abstract][Full Text] [Related]
8. [Phenotypic differences of stroma cells in benign and malignant human prostate tissues]. Zhou H; Sun HB; Huang WB; Xu Z; Su JH; Zhu JG; Jia RP; Liu J Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):516-9. PubMed ID: 22490152 [TBL] [Abstract][Full Text] [Related]
9. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma. Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. van den Brûle FA; Waltregny D; Castronovo V J Pathol; 2001 Jan; 193(1):80-7. PubMed ID: 11169519 [TBL] [Abstract][Full Text] [Related]
11. Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Ishii K; Imanaka-Yoshida K; Yoshida T; Sugimura Y Dev Biol; 2008 Dec; 324(2):310-9. PubMed ID: 18950615 [TBL] [Abstract][Full Text] [Related]
12. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Cardillo MR; Ippoliti F Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460 [TBL] [Abstract][Full Text] [Related]
13. Abnormal G-actin content in single prostate cells as a biomarker of prostate cancer. Hemstreet GP; Bonner RB; Hurst RE; Bell D; Bane BL Cancer Detect Prev; 2000; 24(5):464-72. PubMed ID: 11129989 [TBL] [Abstract][Full Text] [Related]
14. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689 [TBL] [Abstract][Full Text] [Related]
15. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350 [TBL] [Abstract][Full Text] [Related]
16. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Ishihara A; Yoshida T; Tamaki H; Sakakura T Clin Cancer Res; 1995 Sep; 1(9):1035-41. PubMed ID: 9816077 [TBL] [Abstract][Full Text] [Related]
17. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661 [TBL] [Abstract][Full Text] [Related]
18. Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters. Coutinho-Camillo CM; Lourenço SV; da Fonseca FP; Soares FA Pathology; 2011 Feb; 43(2):143-8. PubMed ID: 21233676 [TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Das S; Roth CP; Wasson LM; Vishwanatha JK Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178 [TBL] [Abstract][Full Text] [Related]
20. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]